ReviewDiscover oncology2026
Core clinical procedures and efficacy-enhancing strategies in boron neutron capture therapy.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Boron Neutron Capture Therapy (BNCT) is a binary targeted radiotherapy modality based on nuclear capture reactions. This technique exploits the tumor-targeting capability of boron compounds and their high thermal neutron capture cross-section, inducing localized nuclear reactions within cancer cells that generate α particles and lithium ions. This process enables selective tumor cell destruction at the cellular level. Clinical evidence demonstrates significant therapeutic efficacy of BNCT in treatment-refractory malignancies including glioblastoma, recurrent head and neck carcinomas, and cutaneous melanoma. Compared to conventional radiotherapy, BNCT leverages its inherent biological selectivity to achieve precise eradication of geometrically complex tumors and microscopic metastases, demonstrating significant clinical potential. However, the widespread adoption of BNCT remains constrained by several limitations, most notably the inadequate tumor selectivity of boron delivery agents. This review examines the literature published since the emergence of BNCT clinical research in 1970 up to the present, summarizing key clinical practices and strategies to enhance therapeutic efficacy, including boron carriers, administration regimens, treatment planning systems, real-time boron monitoring, and combination therapies. It aims to provide guidance for the clinical application of BNCT and support its broader adoption in practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.